Implementation of proteomic biomarkers: Making it work

European Journal of Clinical Investigation

Volumn 42, Issue 9, 2012, Pages 1027-1036

  Mischak, Harald ^a,b   Ioannidis, John P A ^c,d,e   Argiles, Angel ^f   Attwood, Teresa K ^g   Bongcam Rudloff, Erik ^h,i   Broenstrup, Mark ^j   Charonis, Aristidis ^k   Chrousos, George P ^l   Delles, Christian ^a   Dominiczak, Anna ^a   Dylag, Tomasz ^m   Ehrich, Jochen ⁿ   Egido, Jesus ^o   Findeisen, Peter ^p   Jankowski, Joachim ^q   Johnson, Robert W ^r   Julien, Bruce A ^s   Lankisch, Tim ⁿ   Leung, Hing Y ^t   Maahs, David ^u   Magni, Fulvio ^v   Manns, Michael P ⁿ   Manolis, Efthymios ^w   Mayer, Gert ^x   Navis, Gerjan ^y   Novak, Jan ^z   Ortiz, Alberto ^o   Persson, Frederik ^aa   Peter, Karlheinz ^ab   Riese, Hans H ^ac   Rossing, Peter ^aa   Sattar, Naveed ^a   Spasovski, Goce ^ad   Thongboonkerd, Visith ^ae   Vanholder, Raymond ^af   Schanstra, Joost P ^ag   Vlahou, Antonia ^k   more..

^a UNIVERSITY OF GLASGOW   (United Kingdom)

^b Mosaiques Diagnostics   (Germany)

^c UNIVERSITY OF IOANNINA   (Greece)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e STANFORD UNIVERSITY   (United States)

^f RD Nephrologie   (France)

^g UNIVERSITY OF MANCHESTER   (United Kingdom)

^h UPPSALA UNIVERSITY   (Sweden)

ⁱ SWEDISH UNIVERSITY OF AGRICULTURAL SCIENCES   (Sweden)

^j SANOFI AVENTIS DEUTSCHLAND GMBH   (Germany)

^k BIOMEDICAL RESEARCH FOUNDATION   (Greece)

^l UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

^m EUROPEAN COMMISSION   (Belgium)

ⁿ HANNOVER MEDICAL SCHOOL   (Germany)

^o UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^p UNIVERSITY OF HEIDELBERG   (Germany)

^q CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

^r ABBOTT LABORATORIES   (United States)

^s University of Alabama at Birmingham   (United States)

^t BEATSON INSTITUTE FOR CANCER RESEARCH   (United Kingdom)

^u UNIVERSITY OF COLORADO DENVER   (United States)

^v UNIVERSITY OF MILANO BICOCCA   (Italy)

^w EUROPEAN MEDICINES AGENCY   (United Kingdom)

^x INNSBRUCK MEDICAL UNIVERSITY   (Austria)

^y UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

^z University of Alabama at Birmingham   (United States)

^aa STENO DIABETES CENTER   (Denmark)

^ab BAKER IDI HEART AND DIABETES INSTITUTE   (Australia)

^ac INSTITUTO DE SALUD CARLOS III   (Spain)

^ad SS CYRIL AND METHODIUS UNIVERSITY OF SKOPJE   (Macedonia)

^ae MAHIDOL UNIVERSITY   (Thailand)

^af GHENT UNIVERSITY HOSPITAL   (Belgium)

^ag University Hospital of Toulouse   (France)

more..

Author keywords

Biomarker; Biomarker implementation; Clinical proteomics; Clinical studies; Expert panel; Proteomics

Indexed keywords

BIOLOGICAL MARKER; CANDESARTAN; INDAPAMIDE PLUS PERINDOPRIL; OLMESARTAN; RAMIPRIL; TRANDOLAPRIL;

ALBUMINURIA; ARTICLE; CLINICAL STUDY; DIABETIC NEPHROPATHY; HEALTH CARE; HUMAN; INTERVENTION STUDY; PRACTICE GUIDELINE; PRIORITY JOURNAL; PROFESSIONAL KNOWLEDGE; PROTEOMICS; QUALITATIVE ANALYSIS; VALIDATION PROCESS; VALIDITY;

BIOLOGICAL MARKERS; BIOMEDICAL RESEARCH; CLINICAL TRIALS AS TOPIC; DRUG DISCOVERY; HUMANS; PROTEOMICS;

EID: 84865194855     PISSN: 00142972     EISSN: 13652362     Source Type: Journal    
DOI: 10.1111/j.1365-2362.2012.02674.x     Document Type: Article

References (45)

1. Merchant ML, Perkins BA, Boratyn GM, Ficociello LH, Wilkey DW, Barati MT et al. Urinary peptidome may predict renal function decline in type 1 diabetes and microalbuminuria. J Am Soc Nephrol 2009;20:2065-74.
2. Good DM, Zürbig P, Argiles A, Bauer HW, Behrens G, Coon JJ et al. Naturally occurring human urinary peptides for use in diagnosis of chronic kidney disease. Mol Cell Proteomics 2010;9:2424-37.
3. Sethi S, Theis JD, Leung N, Dispenzieri A, Nasr SH, Fidler ME et al. Mass spectrometry-based proteomic diagnosis of renal immunoglobulin heavy chain amyloidosis. Clin J Am Soc Nephrol 2010;5:2180-7.
4. Spasovski G, Ortiz A, Vanholder R, El NM. Proteomics in chronic kidney disease: the issues clinical nephrologists need an answer for. Proteomics Clin Appl 2011;5:233-40.
5. Zurbig P, Dihazi H, Metzger J, Thongboonkerd V, Vlahou A. Urine proteomics in kidney and urogenital diseases: moving towards clinical applications. Proteomics Clin Appl 2011;5:256-68.
6. Anderson NL. The clinical plasma proteome: a survey of clinical assays for proteins in plasma and serum. Clin Chem 2010;56:177-85.
7. Semmes OJ, Feng Z, Adam BL, Banez LL, Bigbee WL, Campos D et al. Evaluation of serum protein profiling by surface-enhanced laser desorption/ionization time-of-flight mass spectrometry for the detection of prostate cancer: I. Assessment of platform reproducibility. Clin Chem 2005;51:102-12.
8. Haubitz M, Good DM, Woywodt A, Haller H, Rupprecht H, Theodorescu D et al. Identification and validation of urinary biomarkers for differential diagnosis and evaluation of therapeutic intervention in ANCA associated vasculitis. Mol Cell Proteomics 2009;8:2296-307.
9. Chau CH, Rixe O, McLeod H, Figg WD. Validation of analytic methods for biomarkers used in drug development. Clin Cancer Res 2008;14:5967-76.
10. Lee JW, Hall M. Method validation of protein biomarkers in support of drug development or clinical diagnosis/prognosis. J Chromatogr B Analyt Technol Biomed Life Sci 2009;877:1259-71.
11. Mischak H, Apweiler R, Banks RE, Conaway M, Coon JJ, Dominizak A et al. Clinical Proteomics: a need to define the field and to begin to set adequate standards. Proteomics Clin Appl 2007;1:148-56.
12. Ioannidis JP, Panagiotou OA. Comparison of effect sizes associated with biomarkers reported in highly cited individual articles and in subsequent meta-analyses. JAMA 2011;305:2200-10.
13. Biomarker bias. Nat Med 2012;17:763.
14. Diamandis EP. Cancer biomarkers: can we turn recent failures into success? J Natl Cancer Inst 2010;102:1462-7.
15. Knepper MA. Common sense approaches to urinary biomarker study design. J Am Soc Nephrol 2009;20:1175-8.
16. Mischak H, Allmaier G, Apweiler R, Attwood T, Baumann M, Benigni A et al. Recommendations for biomarker identification and qualification in clinical proteomics. Sci Transl Med 2010;2:46ps42.
17. Ioannidis JP. A roadmap for successful applications of clinical proteomics. Proteomics Clin Appl 2011;5:241-7.
18. Rifai N, Gillette MA, Carr SA. Protein biomarker discovery and validation: the long and uncertain path to clinical utility. Nat Biotechnol 2006;24:971-83.
19. Hood BL, Stewart NA, Conrads TP. Development of high-throughput mass spectrometry-based approaches for cancer biomarker discovery and implementation. Clin Lab Med 2009;29:115-38.
20. Boja ES, Jortani SA, Ritchie J, Hoofnagle AN, Tezak Z, Mansfield E et al. The journey to regulation of protein-based multiplex quantitative assays. Clin Chem 2011;57:560-7.
21. Remily-Wood ER, Liu RZ, Xiang Y, Chen Y, Thomas CE, Rajyaguru N et al. A database of reaction monitoring mass spectrometry assays for elucidating therapeutic response in cancer. Proteomics Clin Appl 2011;5:383-96.
22. Khleif SN, Doroshow JH, Hait WN. AACR-FDA-NCI Cancer Biomarkers Collaborative consensus report: advancing the use of biomarkers in cancer drug development. Clin Cancer Res 2010;16:3299-318.
23. Sattar N. Biomarkers for diabetes prediction, pathogenesis or pharmacotherapy guidance? Past, present and future possibilities. Diabet Med 2012;29:5-13.
24. Ioannidis JP, Khoury MJ. Improving validation practices in "omics" research. Science 2011;334:1230-2.
25. Ioannidis JP, Tzoulaki I. What makes a good predictor?: the evidence applied to coronary artery calcium score. JAMA 2010;303:1646-7.
26. Fleming TR, DeMets DL. Surrogate end points in clinical trials: are we being misled? Ann Intern Med 1996;125:605-13.
27. Ransohoff DF, Khoury MJ. Personal genomics: information can be harmful. Eur J Clin Invest 2010;40:64-8.
28. Ruggenenti P, Fassi A, Ilieva AP, Bruno S, Iliev IP, Brusegan V et al. Preventing microalbuminuria in type 2 diabetes. N Engl J Med 2004;351:1941-51.
29. Haller H, Ito S, Izzo JL Jr, Januszewicz A, Katayama S, Menne J et al. Olmesartan for the delay or prevention of microalbuminuria in type 2 diabetes. N Engl J Med 2011;364:907-17.
30. Dylag T, Jehenson P, van de Loo JW, Sanne JL. Basic and clinical proteomics from the EU Health Research perspective. Proteomics Clin Appl 2010;4:888-91.
31. Mischak H, Rossing P. Proteomic biomarkers in diabetic nephropathy--reality or future promise? Nephrol Dial Transplant 2010;25:2843-5.
32. Verma M, Wright GL Jr, Hanash SM, Gopal-Srivastava R, Srivastava S. Proteomic approaches within the NCI early detection research network for the discovery and identification of cancer biomarkers. Ann N Y Acad Sci 2001;945:103-15.
33. Manolis E, Vamvakas S, Isaac M. New pathway for qualification of novel methodologies in the European medicines agency. Proteomics Clin Appl 2011;5:248-55.
34. Keogh B. European biobanks forge cross-border ties. J Natl Cancer Inst 2011;103:1429-31.
35. Murtagh MJ, Demir I, Harris JR, Burton PR. Realizing the promise of population biobanks: a new model for translation. Hum Genet 2011;130:333-45.
36. Mitchell R, Conley JM, Davis AM, Cadigan RJ, Dobson AW, Gladden RQ. Genomics. Genomics, biobanks, and the trade-secret model. Science 2011;332:309-10.
37. Budimir D, Polasek O, Marusic A, Kolcic I, Zemunik T, Boraska V et al. Ethical aspects of human biobanks: a systematic review. Croat Med J 2011;52:262-79.
38. Kaye J. From single biobanks to international networks: developing e-governance. Hum Genet 2011;130:377-82.
39. Wichmann HE, Kuhn KA, Waldenberger M, Schmelcher D, Schuffenhauer S, Meitinger T et al. Comprehensive catalog of European biobanks. Nat Biotechnol 2011;29:795-7.
40. Poste G. Bring on the biomarkers. Nature 2011;469:156-7.
41. Chaturvedi N, Porta M, Klein R, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on prevention (DIRECT-Prevent 1) and progression (DIRECT-Protect 1) of retinopathy in type 1 diabetes: randomised, placebo-controlled trials. Lancet 2008;372:1394-402.
42. Sjolie AK, Klein R, Porta M, Orchard T, Fuller J, Parving HH et al. Effect of candesartan on progression and regression of retinopathy in type 2 diabetes (DIRECT-Protect 2): a randomised placebo-controlled trial. Lancet 2008;372:1385-93.
43. Bilous R, Chaturvedi N, Sjolie AK, Fuller J, Klein R, Orchard T et al. Effect of candesartan on microalbuminuria and albumin excretion rate in diabetes: three randomized trials. Ann Intern Med 2009;151:11-4.
44. Heart Outcomes Prevention Evaluation (HOPE) Study Investigators. Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Heart Outcomes Prevention Evaluation Study Investigators. Lancet 2000;355:253-9.
45. Patel A, MacMahon S, Chalmers J, Neal B, Woodward M, Billot L et al. Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial. Lancet 2007;370:829-40.